Lapaquistat

Lapaquistat (TAK-475) is a cholesterol-lowering drug. Unlike statins which inhibit HMG-CoA reductase, lapaquistat metabolites inhibit squalene synthase which is further downstream in the synthesis of cholesterol. It is hoped that side effects can be reduced by not disturbing the mevalonate pathway which is important for other biochemical molecules besides cholesterol. However, there is increasing evidence that statins (which inhibit the mevalonate pathway) may be clinically useful because they affect these other molecules (including protein prenylation) Greenwood et al., 2006. It remains to be seen how effective lapaquistat will be.

On March 28, 2008, Takeda halted further development of lapaquistat.^[1]

• Davidson MH (2007). “Squalene synthase inhibition: a novel target for the management of dyslipidemia”. Curr Atheroscler Rep. 9 (1): 78–80. PMID 17169251. Unknown parameter |month= ignored (help)

Template:Lipid modifying agents

Template:WikiDoc Sources